finnCap disclosed Premaitha Health Plc (LON:NIPT), retaining its price target at 20.00GBX earlier today
- Updated: October 1, 2016
Showing a price of 11.00GBX, Premaitha Health Plc (LON:NIPT) traded -6.74% lower on the day. With the last stock price close up 8.26% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. NIPT has recorded a 50-day moving average of 10.45GBX and a 200-day moving average of 9.58GBX. 2,450,616 shares of the stock were exchanged, up from an average trading volume of 821,670
Reporting a potential upside of 0.82%, finnCap hold steady the price target of Premaitha Health Plc (LON:NIPT) at 20.00GBX
On 8/30/2016, finnCap released a statement on Premaitha Health Plc (LON:NIPT) maintained the target price at 20.00GBX that suggested an upside of 0%.
See Chart Below
Premaitha Health Plc has a 52 week low of 6.50GBX and a 52 week high of 21.50GBX The company’s market cap is currently 0 GBX.
In addition to finnCap reporting its target price, a total of 2 firms have issued a report on the stock. The consensus target price is 22.00GBX with 0 firms rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Premaitha Health Plc (LON:NIPT)
Premaitha Health PLC, formerly ViaLogy plc, is engaged in molecular diagnostics business for research, and the development and commercialization of gene analysis techniques. The Company's techniques are used for pre-natal screening (NIPT) and other clinical applications in the early detection, monitoring and treatment of disease. The Company operates through two segments: Head office and Operations. The Operations segment is involved in a molecular diagnostics business in the United Kingdom, and sales technology development in the United States. The Company's flagship product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated NIPT in-house. The IONA test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The IONA test directly measures alterations in deoxyribonucleic acid ratios in the maternal plasma when fetal trisomy 21, 18 or 13 is present.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.